StreetInsider.com News Articles

Allogene's CAR T therapy shows 31% response rate in kidney cancer

Wed, 15 Jul 2026 08:30:24 -0400

Allogene Therapeutics (Nasdaq: ALLO) announced the publication of complete Phase 1 data from its TRAVERSE study of ALLO-316, an allogeneic CAR T therapy targeting CD70, in the Journal of Clinical Oncology. The trial evaluated the treatment in patients with advanced or metastatic renal cell carcinoma (RCC).

In the Phase 1b expansion cohort, which used the recommended Phase 2 regimen of 80 million CAR T cells following standard lymphodepletion, 20 patients received ALLO-316. Of 16 patients with high CD70 tumor proportion scores (TPS ≥50%), five responded, representing a 31% confirmed response rate. The overall confirmed response rate across all 20 treated patients

Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Sol

Wed, 15 Jul 2026 08:30:00 -0400

ALLO-316 Achieved a 31% Confirmed Response Rate with the Recommended Phase 2 Regimen in Patients with Stage IV Renal Cell Carcinoma (RCC) with High CD70 Expression
- Single Dose of ALLO-316 Produced Durable Responses in this Cohort with All Responders Progression-Free at the Time of Analysis
- Responses Range from 8 to 18+ Months, with Median Overall Survival Not Yet Reached
Safety Profile was Manageable with Proactive Diagnostic and Management Strategies Effective in Mitigating IEC-HS
ALLO-316 Demonstrated Robust Expansion and Tumor Infiltration Following Standard Lymphodepletion, Validating the Dagger^® Technology as a Next-Generation Allogeneic CAR T Platform

SOUTH SAN

Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Sol

Wed, 15 Jul 2026 08:30:00 -0400

ALLO-316 Achieved a 31% Confirmed Response Rate with the Recommended Phase 2 Regimen in Patients with Stage IV Renal Cell Carcinoma (RCC) with High CD70 Expression
- Single Dose of ALLO-316 Produced Durable Responses in this Cohort with All Responders Progression-Free at the Time of Analysis
- Responses Range from 8 to 18+ Months, with Median Overall Survival Not Yet Reached
Safety Profile was Manageable with Proactive Diagnostic and Management Strategies Effective in Mitigating IEC-HS
ALLO-316 Demonstrated Robust Expansion and Tumor Infiltration Following Standard Lymphodepletion, Validating the Dagger^® Technology as a Next-Generation Allogeneic CAR T Platform

SOUTH SAN

Form 4 Allogene Therapeutics, For: Jul 01 Filed by: Roberts Zachary

Mon, 06 Jul 2026 17:51:00 -0400

si-local-file:///var/storage/secattach/20260706/26736832.html

Form 4 Allogene Therapeutics, For: Jul 01 Filed by: Roberts Zachary

Mon, 06 Jul 2026 17:51:00 -0400

si-local-file:///var/storage/secattach/20260706/26736832.html

Form 4 Allogene Therapeutics, For: Jun 18 Filed by: Kazam Joshua A

Tue, 23 Jun 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260623/26680028.html

Form 4 Allogene Therapeutics, For: Jun 18 Filed by: Kazam Joshua A

Tue, 23 Jun 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260623/26680028.html

Form 4 Allogene Therapeutics, For: Jun 18 Filed by: MESSEMER DEBORAH M.

Tue, 23 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260623/26680011.html

Form 4 Allogene Therapeutics, For: Jun 18 Filed by: MESSEMER DEBORAH M.

Tue, 23 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260623/26680011.html

Form 4 Allogene Therapeutics, For: Jun 18 Filed by: Mayo Stephen

Tue, 23 Jun 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260623/26679994.html

Form 4 Allogene Therapeutics, For: Jun 18 Filed by: Mayo Stephen

Tue, 23 Jun 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260623/26679994.html

Form 4 Allogene Therapeutics, For: Jun 18 Filed by: SATO VICKI L

Tue, 23 Jun 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260623/26679984.html

Form 4 Allogene Therapeutics, For: Jun 18 Filed by: SATO VICKI L

Tue, 23 Jun 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260623/26679984.html

Form 4 Allogene Therapeutics, For: Jun 18 Filed by: WITTE OWEN N.

Tue, 23 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260623/26679902.html

Form 4 Allogene Therapeutics, For: Jun 18 Filed by: WITTE OWEN N.

Tue, 23 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260623/26679902.html

Form 4 Allogene Therapeutics, For: Jun 18 Filed by: Humer Franz B

Tue, 23 Jun 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260623/26679852.html

Form 4 Allogene Therapeutics, For: Jun 18 Filed by: Humer Franz B

Tue, 23 Jun 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260623/26679852.html

Form 4 Allogene Therapeutics, For: Jun 18 Filed by: Barrett Elizabeth A.

Tue, 23 Jun 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260623/26679833.html

Form 4 Allogene Therapeutics, For: Jun 18 Filed by: Barrett Elizabeth A.

Tue, 23 Jun 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260623/26679833.html

Form 8-K Allogene Therapeutics, For: Jun 18

Mon, 22 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260622/26673017.html

Form 8-K Allogene Therapeutics, For: Jun 18

Mon, 22 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260622/26673017.html

Form 424B5 Allogene Therapeutics,

Mon, 22 Jun 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260622/26672941.html

Form 424B5 Allogene Therapeutics,

Mon, 22 Jun 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260622/26672941.html

Form DEFA14A Allogene Therapeutics,

Thu, 28 May 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260528/26568825.html

Form DEFA14A Allogene Therapeutics,

Thu, 28 May 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260528/26568825.html